# Tagrisso® (osimertinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/osimertinib

> The next catalyst for Tagrisso® (osimertinib), sponsored by ASTRAZENECA PLC (AZN), is its topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tagrisso® (osimertinib) |
| Codes | AZD9291 |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Stage II-IIIB Non-small Cell Lung Carcinoma](https://sec-api.dev/indications/stage-ii-iiib-non-small-cell-lung-carcinoma), [Cancer](https://sec-api.dev/indications/cancer), [Metastatic Non-small Cell Lung Cancer](https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer), [Non-Small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc), [Carcinoma](https://sec-api.dev/indications/carcinoma), [Lung Cancer](https://sec-api.dev/indications/lung-cancer) |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, priority review |

## Timeline

### May 23, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200523, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### December 9, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20201209, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22
- openFDA Drugs@FDA: "NDA208065 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-06-11, last confirmed 2025-06-11.
- SEC Form 8-K (accession 0001437749-25-020102): "Genprex opened the Phase 2a expansion portion of the study and enrolled and dosed the first patient in January 2024." https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm

### January 31, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20240131, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### February 16, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20240216, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### September 25, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20240925, review_priority PRIORITY; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### May 2025: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03944772 (Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03944772

### March 31, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-05-05, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001104659-26-055318): "Since our inception through March 31, 2026, our main activities have been organizational management,capital raising and the completion of the in-license agreements for, NXP800 and NXP900, regulatory filings with the Medicines and Healthcare products Regulatory Agency ("MHRA") and FDA, preparation and execution for the Phase 1a and Phase 1b clinical trial for NXP800, which commenced in December 2021 and May 2023, respectively, and Phase 1a, Phase 1b (single agent) and Phase 1b (combination study with osimertinib) clinical trials for NXP900, which commenced in September 2023, August 2025 and December 2025, respectively." https://www.sec.gov/Archives/edgar/data/1875558/000110465926055318/tmb-20260331x10q.htm

### July 6, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Carcinoma; Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05261399 (Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05261399

### July 7, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06194448 (To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06194448

### September 14, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208065 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20260914, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06417814

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metastatic Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06417814

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05629234 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05629234

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05629234 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05629234

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05120349

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05120349

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05801029

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05801029

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06350097

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06350097

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07295821 (Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07295821

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07295821 (Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07295821

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05546866

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05546866

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Stage II-IIIB Non-small Cell Lung Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05526755 (A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05526755

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Stage II-IIIB Non-small Cell Lung Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05526755 (A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05526755

## Same indication

- [9-ing-41](https://sec-api.dev/pdufa/9-ing-41) (ACTU)
- [CABOMETYX® (cabozantinib)](https://sec-api.dev/pdufa/cabozantinib) (EXEL)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Jemperli (dostarlimab)](https://sec-api.dev/pdufa/dostarlimab) (GSK)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)
- [Platinum based chemotherapy](https://sec-api.dev/pdufa/platinum-based-chemotherapy) (NVCR)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Rp1](https://sec-api.dev/pdufa/rp1) (REPL)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)
- [Zimberelimab (zim)](https://sec-api.dev/pdufa/zimberelimab-zim) (GILD)

Calendar months: [May 2025](https://sec-api.dev/fda-calendar/2025-05), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [August 2027](https://sec-api.dev/fda-calendar/2027-08), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/osimertinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tagrisso® (osimertinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/osimertinib

```bibtex
@misc{secapidev_pdufa_osimertinib_20261116,
  title        = {Tagrisso® (osimertinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/osimertinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_osimertinib_20261116","title":"Tagrisso® (osimertinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/osimertinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
